Gilead joins a line­up of Big Phar­ma part­ners bet­ting big on TriN­KETs, with a $300M cash ante to get start­ed on a 5T4

Bill Haney’s Drag­on­fly Ther­a­peu­tics is mak­ing the vault be­tween biotech start­up and the next big lev­el: adding clin­i­cal-stage com­pounds to its own fledg­ling pipeline while wel­com­ing an­oth­er Big Phar­ma name to a line­up of in­dus­try part­ner­ships that are now mov­ing to­ward their own clin­i­cal des­tinies.

Un­char­ac­ter­is­tic of the new gen­er­a­tion of star­tups, Haney — who has stead­fast­ly avoid­ed the lime­light of pub­lic com­pa­ny sta­tus, now turned in­to a harsh spot­light for many — just scored a ma­jor pre­clin­i­cal deal with Gilead that con­tributes $300 mil­lion to the cash re­serves at Drag­on­fly.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE